Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.58 |
| ▸ | GSK3B | P49841 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16938818 | 0.84 | MAPT (0.63) | MAPTALDH1A1KMT2AMEN1KDM4E | |
| SCHEMBL27519955 | 0.84 | MAPT (0.63) | MAPTALDH1A1KMT2AMEN1KDM4E | |
| SCHEMBL10747787 | 0.84 | MAPT (0.62) | MAPTALDH1A1KMT2AMEN1KDM4E | |
| SCHEMBL671514 | 0.81 | GSK3B (0.67) | ALDH1A1GSK3BMAPK1 | |
| SCHEMBL28964071 | 0.81 | MAPT (0.62) | MAPTALDH1A1KMT2AMEN1KDM4E | |
| SCHEMBL13531982 | 0.80 | GSK3B (0.61) | MAPTALDH1A1KMT2AMEN1KDM4E | |
| SCHEMBL2738370 | 0.80 | BCL9 (0.66) | MAPTALDH1A1KMT2APOLBSMN1; SMN2 | |
| SCHEMBL16399225 | 0.79 | MAPT (0.72) | MAPTALDH1A1KMT2AMEN1KDM4E | |
| SCHEMBL11461528 | 0.78 | HTT (0.57) | MAPTALDH1A1KMT2AMEN1NPC1 | |
| SCHEMBL9200565 | 0.78 | ALDH1A1 (0.60) | MAPTALDH1A1KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8410155-B2 | Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor XIA inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-02 | — | — | US | disclosed |
| US-20100016316-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016316-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | F12, TFPI, F11 | MAPT 1192/4885ALDH1A1 2528/4885KMT2A 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.